Harlow John B. Jr. purchased $50K of LRMR

Harlow John B. Jr. (President and COO) purchased 17,800 shares of Larimar Therapeutics, Inc. (LRMR) at $2.80 on 2026-11-11.

Original reporting
SEC EDGAR · Harlow John B. Jr.
Published Nov 12, 2026, 11:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 11:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LRMR
Bullish
medium confidence
Mentioned
$LRMR
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LRMRBullishLow
01

Why it matters

The filing provides fresh information on insider confidence but limited market impact due to small size.

02

Market read

New insider purchase adds modest positive sentiment but unlikely to move the stock significantly.

03

What to watch

Potential upcoming clinical data could be the real driver, not the insider trade.

Relevance 4/10Novelty 4/10Timing: today

Background

Larimar Therapeutics filed a Form 4 showing an insider purchase.

Company-level read

Ticker impact

$LRMRBullishMedium confidence
Context

Form 4 disclosed President/COO bought 17,800 shares for $49,918, increasing his stake to 67,800 shares.

Expected impact

likely modest upward pressure as market prices in insider confidence

Evidence & confidence

Purchase amount is modest ($50K) but insider role adds credibility; impact limited.

Market effects

Minimal effect on biotech sector; typical insider activity.

None

None

Counterpoint

The purchase is too small to signal material change; price may remain unchanged.

Key entities

  • Larimar Therapeutics, Inc.

    Biotech firm listed on Nasdaq (LRMR).

  • Harlow John B. Jr.

    President and COO of Larimar Therapeutics.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LRMRMed

Larimar Therapeutics Reports Third Quarter 2026 Financial and Business Update

Larimar Therapeutics, Inc. (LRMR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Larimar Therapeutics Reports Third Quarter 2026 Financial and Business Update • Completed BLA submission seeking accelerated approval of nomlabofusp for adults and pediatric patients with FA; potential to be the first disease-modifying therapy to address root cause o

$LRMRMed

Larimar Therapeutics, Inc. (LRMR): Results of Operations and Financial Condition

Larimar Therapeutics, Inc. (LRMR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Larimar Therapeutics Completes Rolling BLA Submission Seeking Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia • Completed BLA submission marks a major milestone in advancing nomlabofusp as the first potential disease-modifying therapy to address the under

$LRMRMed

Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update

Larimar Therapeutics, Inc. (LRMR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update • Positive longer-term open label study data further demonstrated nomlabofusp's well-characterized safety profile, sustained increases in skin frataxin levels, and continued improvements in key clinica

$LRMRMed

Larimar Therapeutics (LRMR) Submits Initial Module of BLA For Nomlabofusp Therapy

Larimar Therapeutics (NASDAQ:LRMR) filed the first module of its Biologics License Application with the U.S. FDA for Nomlabofusp therapy on an accelerated basis, with additional modules planned in the second half of 2026. The company cited positive open-label study results in adult Friedreich’s ataxia patients and said FDA confirmed existing data supports the submission using skin frataxin as a surrogate endpoint. Baird cut its price target to $5 from $7 while keeping an Outperform rating.